Synchrony Medical, a respiratory technology innovator, announced Monday that it secured a $1 million investment from the New Jersey Innovation Evergreen Fund (NJIEF). The funding matches a previous investment from Edge Medical Ventures and is earmarked to scale the commercial launch of the company’s LibAirty™ Airway Clearance System across the United States.
This injection of capital reinforces New Jersey’s standing as a premier hub for medtech, with Synchrony Medical establishing its U.S. headquarters in Jersey City. The move follows the system’s FDA 510(k) clearance in late 2024, positioning the company to address a massive unmet need for patients suffering from chronic lung conditions.
The LibAirty™ system is a first-of-its-kind wearable vest designed for patients with COPD, bronchiectasis, and cystic fibrosis. Unlike traditional “chest wall oscillation” vests that use simple vibration, LibAirty™ uses a proprietary technology inspired by Autogenic Drainage—a sophisticated breathing technique typically taught by specialized respiratory therapists.
By synchronizing targeted chest compressions with guided breathing via a mobile app, the system helps clear mucus from the deepest, hardest-to-reach parts of the lungs. Clinical trials at the Medical University of South Carolina (MUSC) and Sheba Medical Center showed that LibAirty™ was twice as effective as standard vest-based therapies.
“Synchrony’s vision is to fundamentally change how chronic lung disease is treated at home,” Anat Shani, CEO of Synchrony Medical said. “This funding accelerates our ability to expand patient access to LibAirty™ nationwide.”
The investment was made through the New Jersey Innovation Evergreen Fund (NJIEF), a unique public-private partnership managed by the NJEDA. The fund is designed to attract high-growth tech companies to the state by matching investments from qualified venture firms.
“Synchrony is well-positioned to lead the airway clearance market,” Shai Policker, managing partner at Edge Medical Ventures said. “We are already seeing clear signs of commercial traction.”
Synchrony Medical plans to use the $1 million in new capital to:
-
Accelerate Commercialization: Building out a national sales force to partner with respiratory clinics and homecare networks.
-
Clinical Research: Funding ongoing studies to monitor long-term outcomes, such as reduced hospitalization rates for COPD patients.
-
Product Development: Enhancing the digital app interface to provide better real-time data to physicians.
The company’s growth in Jersey City is expected to create high-skilled jobs in medical device engineering and clinical support, further validating the NJEDA’s mission to anchor breakthrough technology within the state.
